BidaskClub upgraded shares of Progenics Pharmaceuticals (NASDAQ:PGNX) from a sell rating to a hold rating in a report issued on Wednesday.
A number of other equities research analysts have also recently weighed in on the stock. Cantor Fitzgerald set a $15.00 price target on shares of Progenics Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, January 2nd. ValuEngine raised shares of Progenics Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, December 7th. Finally, Zacks Investment Research cut shares of Progenics Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $12.35.
Shares of Progenics Pharmaceuticals (PGNX) opened at $5.97 on Wednesday. Progenics Pharmaceuticals has a 1 year low of $4.60 and a 1 year high of $11.72. The firm has a market cap of $432.55, a price-to-earnings ratio of -7.56 and a beta of 3.40. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.80.
Large investors have recently made changes to their positions in the company. Piedmont Investment Advisors LLC purchased a new stake in shares of Progenics Pharmaceuticals in the second quarter valued at about $103,000. Aperio Group LLC purchased a new stake in shares of Progenics Pharmaceuticals in the third quarter valued at about $118,000. Fox Run Management L.L.C. purchased a new stake in shares of Progenics Pharmaceuticals in the fourth quarter valued at about $100,000. Metropolitan Life Insurance Co. NY purchased a new stake in shares of Progenics Pharmaceuticals in the fourth quarter valued at about $101,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Progenics Pharmaceuticals in the fourth quarter valued at about $142,000. 84.53% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Progenics Pharmaceuticals (PGNX) Raised to “Hold” at BidaskClub” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/02/18/progenics-pharmaceuticals-pgnx-raised-to-hold-at-bidaskclub-2.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.